ASX listed drug developer, Immuron (ASX: IMC) has dealt itself very firmly into the high profile, and potentially high return influenza treatment market.
Immuron has entered into discussions with a top-25 global pharmaceutical company, with a potential joint development of Immuron’s influenza treatment and prevention product.
As indicated previously, Immuron has achieved very positive results in pre-clinical (animal) trials on its influenza product.
Clearly, this is an important step in the evolution of Immuron as it scientifically and commercially progresses its new influenza product.
Immuron is continuing to attract interest in assisting with the scientific development and commercialisation of products from its pipeline.